1. Home
  2. LKFN vs NRIX Comparison

LKFN vs NRIX Comparison

Compare LKFN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

HOLD

Current Price

$58.27

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$16.47

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKFN
NRIX
Founded
1872
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
LKFN
NRIX
Price
$58.27
$16.47
Analyst Decision
Buy
Strong Buy
Analyst Count
3
14
Target Price
$67.00
$26.50
AVG Volume (30 Days)
127.2K
1.6M
Earning Date
10-27-2025
10-09-2025
Dividend Yield
3.42%
N/A
EPS Growth
N/A
N/A
EPS
3.79
N/A
Revenue
$248,271,000.00
$83,687,000.00
Revenue This Year
$17.16
$58.48
Revenue Next Year
$3.98
N/A
P/E Ratio
$15.41
N/A
Revenue Growth
2.85
48.32
52 Week Low
$50.00
$8.18
52 Week High
$75.64
$23.00

Technical Indicators

Market Signals
Indicator
LKFN
NRIX
Relative Strength Index (RSI) 47.91 67.18
Support Level $57.40 $16.63
Resistance Level $59.55 $17.79
Average True Range (ATR) 1.63 1.02
MACD 0.29 0.21
Stochastic Oscillator 57.02 75.17

Price Performance

Historical Comparison
LKFN
NRIX

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: